Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics
This article was originally published in PharmAsia News
Executive SummaryTOKYO - Nichi-Iko has upped its capability to bring biosimilars to the Japanese market, buying a 33 percent stake in South Korean biosimilar firm Aprogen, giving the Japanese generics maker exclusive rights to Aprogen products in Japan
You may also be interested in...
A joint venture with Korean conglomerate Samsung will be limited to making generic versions of non-Biogen products, although Samsung separately is working on a biosimilar of rituximab.
The $300 million Korean joint venture gives Samsung a global stage but raises questions about its Rituxan biosimilars program.